Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul;53(5):543-544.
doi: 10.1016/j.arcmed.2022.05.004. Epub 2022 May 25.

Utility of Serum S100B as A Marker in Systemic Lupus Erythematosus Patients During and After the SARS-CoV-2 Pandemic

Elena Noris-García  1 , Maria DE Los Angeles Robinson-Agramonte  2 , Carlos-Alberto Gonçalves  3
Affiliations
Comment

Utility of Serum S100B as A Marker in Systemic Lupus Erythematosus Patients During and After the SARS-CoV-2 Pandemic

Elena Noris-García et al. Arch Med Res. 2022 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interests The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Potential mechanisms by which glial reactivity may be induced in NPSLE patients with COVID-19 (1). In the first condition, the inflammatory impact of the rheumatic disease on intact astrocytes in the CNS (in SLE) initially triggers the glial reactivity found in NPSLE, characterized by increased GFAP expression (with or without its release to the extracellular space) and increased secretion of S100B (2). In the second condition, the cytokine storm induced by SARS-CoV-2 (along with hypoxemia and thrombotic events) produces glial reactivity, which may or may not overlap with condition 1 (3). In the third condition, SARS-CoV-2 directly causes glial reactivity (neuroinfection), which may or may not overlap with condition 1.
See this image and copyright information in PMC

Comment in

Comment on

  • Emerging Roles of Coronavirus in Autoimmune Diseases.
    Zhou SY, Zhang C, Shu WJ, Chong LY, He J, Xu Z, Pan HF. Zhou SY, et al. Arch Med Res. 2021 Oct;52(7):665-672. doi: 10.1016/j.arcmed.2021.03.012. Epub 2021 Apr 8. Arch Med Res. 2021. PMID: 33875273 Free PMC article. Review.

References

    1. Zhou S-Y, Zhang C, Shu W-J, et al. Emerging Roles of Coronavirus in Autoimmune Diseases. Arch Med Res. 2021;52:665–672. doi: 10.1016/j.arcmed.2021.03.012. - DOI - PMC - PubMed
    1. Robinson-Agramonte MA, Gonçalves C-A, Noris-García E, et al. Impact of SARS-CoV-2 on neuropsychiatric disorders. World J Psychiatry. 2021;11:347–354. doi: 10.5498/wjp.v11.i7.347. - DOI - PMC - PubMed
    1. Miners S, Kehoe PG, Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimers Res Ther. 2020;12:170. - PMC - PubMed
    1. Aceti A, Margarucci LM, Scaramucci E, et al. Serum S100B protein as a marker of severity in Covid-19 patients. Sci Rep. 2020;10:18665. doi: 10.1038/s41598-020-75618-0. - DOI - PMC - PubMed
    1. Pilotto A, Masciocchi S, Volonghi I, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. Clin Infect Dis. 2021;73:e3019–e3026. doi: 10.1093/cid/ciaa1933. - DOI - PMC - PubMed

Substances